Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy

被引:0
|
作者
Daniel P. Judge
David A. Kass
W. Reid Thompson
Kathryn R. Wagner
机构
[1] Johns Hopkins University,Division of Cardiology/Medicine
[2] Hugo W. Moser Research Institute at Kennedy Krieger,Department of Biomedical Engineering
[3] Université Paris Descartes,Division of Cardiology/Pediatrics
[4] Sorbonne Paris Cité,Department of Neurology
[5] Johns Hopkins University,undefined
[6] Johns Hopkins University,undefined
[7] Johns Hopkins University,undefined
关键词
Losartan; Carvedilol; Duchenne Muscular Dystrophy; Cardiac Dysfunction; Perindopril;
D O I
暂无
中图分类号
学科分类号
摘要
Cardiac dysfunction is a frequent manifestation of Duchenne muscular dystrophy (DMD) and a common cause of death for individuals with this condition. Early diastolic dysfunction and focal fibrosis proceed to dilated cardiomyopathy (DCM), complicated by heart failure and arrhythmia in most patients. Improvements in the management of respiratory insufficiency in DMD have improved lifespan and overall prognosis, but heart failure and sudden death continue to impact survival and quality of life for people with DMD. Since the specific mechanisms resulting in heart failure for people with DMD are poorly understood, current treatments are not targeted, but rely on approaches that are considered standard for DCM. These approaches include angiotensin-converting enzyme (ACE) inhibitors and β-adrenoceptor antagonists. Data from one trial in DMD support the use of ACE inhibitors before the onset of left ventricular dysfunction. Angiotensin receptor blockers have shown similar efficacy to ACE inhibitors in numerous studies of dilated cardiomyopathy, and are a good choice for patients who cannot tolerate ACE inhibition. The pathogenesis of DMD-associated cardiomyopathy may be similar to other genetic disorders of the cytoskeletal complex of ventricular myocytes, though unique features offer targeted opportunities to impact treatment. Novel areas of investigation are focused on the regulatory role of dystrophin in relation to neuronal nitric oxide synthase (nNOS) and transient receptor potential canonical channels (TRPC). Inhibition of phosphodiesterase-5 (PDE5) addresses several aspects of regulatory dysfunction induced by dystrophin deficiency, and studies with PDE5-inhibitors have shown benefits in murine models of DMD. PDE5-inhibitors are currently under investigation in at least one study in humans. This article focuses on mechanisms of cardiac dysfunction, as well as potential targets for pharmacologic manipulation to prevent or improve cardiomyopathy in DMD.
引用
收藏
页码:287 / 294
页数:7
相关论文
共 50 条
  • [1] Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy
    Judge, Daniel P.
    Kass, David A.
    Thompson, W. Reid
    Wagner, Kathryn R.
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2011, 11 (05) : 287 - 294
  • [2] Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy
    Meyers, Tatyana A.
    Townsend, DeWayne
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (17)
  • [3] Duchenne muscular dystrophy pathophysiology
    Pereon, Y.
    Mercier, S.
    Magot, A.
    [J]. ARCHIVES DE PEDIATRIE, 2015, 22 : S18 - S23
  • [4] Steroid Therapy and Cardiac Function in Duchenne Muscular Dystrophy
    L.W. Markham
    R.L. Spicer
    P.R. Khoury
    B.L. Wong
    K.D. Mathews
    L.H. Cripe
    [J]. Pediatric Cardiology, 2005, 26 : 768 - 771
  • [5] Cardiac Dysfunction in Duchenne Muscular Dystrophy: Role of Connexin 43
    Fraidenrach, Diego
    Gonzalez, Patrick
    Shirokova, Natalia
    Ramachandran, Jayalakshmi
    Contreras, Jorge E.
    [J]. JOURNAL OF GENERAL PHYSIOLOGY, 2016, 148 (02): : 11A - 11A
  • [6] Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy
    Mourkioti, Foteini
    Kustan, Jackie
    Kraft, Peggy
    Day, John W.
    Zhao, Ming-Ming
    Kost-Alimova, Maria
    Protopopov, Alexei
    DePinho, Ronald A.
    Bernstein, Daniel
    Meeker, Alan K.
    Blau, Helen M.
    [J]. NATURE CELL BIOLOGY, 2013, 15 (08) : 895 - U300
  • [7] Correlation of Heart Rate and Cardiac Dysfunction in Duchenne Muscular Dystrophy
    Thomas, Tamara O.
    Morgan, Thomas M.
    Burnette, William B.
    Markham, Larry W.
    [J]. PEDIATRIC CARDIOLOGY, 2012, 33 (07) : 1175 - 1179
  • [8] Steroid therapy and cardiac function in Duchenne muscular dystrophy
    Markham, LW
    Spicer, RL
    Khoury, PR
    Wong, BL
    Mathews, KD
    Cripe, LH
    [J]. PEDIATRIC CARDIOLOGY, 2005, 26 (06) : 768 - 771
  • [9] Correlation of Heart Rate and Cardiac Dysfunction in Duchenne Muscular Dystrophy
    Tamara O. Thomas
    Thomas M. Morgan
    William B. Burnette
    Larry W. Markham
    [J]. Pediatric Cardiology, 2012, 33 : 1175 - 1179
  • [10] CAVEOLAR DYSFUNCTION AS A NEWPLAYER IN CARDIAC DISEASE IN DUCHENNE MUSCULAR DYSTROPHY
    Marrosu, Elena
    Wang, Hong
    Johnson, Eric
    Scott, Charlotte
    Hau, Kwan-Leong
    Zhang, Liwen
    Duan, Nalinda Wasala Dongsheng
    Montanaro, Federica
    [J]. CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (02) : 274 - 275